Long-term femoral vein central venous access in cancer patients

Sergio Bertoglio, Carmine DiSomma, Paolo Meszaros, Marco Gipponi, Ferdinando Cafiero, Pierluigi Percivale

Research output: Contribution to journalArticlepeer-review


Subclavian percutaneous access with reservoir placement has been shown to be difficult or contraindicated in some patients. Of 465 cancer patients who required a port placement between January 1992 to January 1995, 41 (8.8%) had alternative percutaneous femoral access with a totally implantable port reservoir located in the abdomen because of the inaccessibility to subclavian or jugular veins and/or the presence of massive cutaneous metastases or severe radiodermitis in the upper part of the torso. Overall implant days was 9880, with an average of 241 days (range: 65-445). Ports were alternatively used for chemotherapy and nutritional purposes in 11 of 41 patients. Late morbidity causing the removal of the implanted ports was observed in two of 41 (4.9%) and in 25 of 424 (5.9%) patients in the femoral and subclavian series, respectively (P = 0.86). The femoral percutaneous access for totally implantable port devices appears to be a safe alternative for cancer patients when subclavian and/or jugular vein catheterization and reservoir in the upper part of the torso is contraindicated.

Original languageEnglish
Pages (from-to)162-165
Number of pages4
JournalEuropean Journal of Surgical Oncology
Issue number2
Publication statusPublished - 1996


  • Central venous catheterization
  • Neoplasm
  • Ports
  • Surgery
  • Venous access

ASJC Scopus subject areas

  • Oncology
  • Surgery


Dive into the research topics of 'Long-term femoral vein central venous access in cancer patients'. Together they form a unique fingerprint.

Cite this